FGFR1 Solid Tumor Test: Comprehensive Genetic Analysis for Precision Oncology
Understanding the FGFR1 Solid Tumor Test
The FGFR1 Solid Tumor Test represents a cutting-edge advancement in molecular oncology diagnostics, specifically designed to detect genetic alterations in the Fibroblast Growth Factor Receptor 1 (FGFR1) gene. This sophisticated test utilizes FISH (Fluorescence In Situ Hybridization) technology to analyze tumor tissue samples, providing crucial information about the genetic drivers of cancer progression. FGFR1 plays a vital role in cell growth, division, and survival, and when mutated or amplified, it can become a powerful driver of tumor development and metastasis.
What the FGFR1 Test Measures and Detects
The FGFR1 Solid Tumor Test specifically identifies:
- FGFR1 gene amplifications and copy number variations
- Chromosomal rearrangements involving the FGFR1 locus
- Gene fusion events that may activate oncogenic signaling pathways
- Specific genetic alterations that make tumors susceptible to targeted therapies
- Molecular markers that predict response to FGFR inhibitors
Who Should Consider the FGFR1 Solid Tumor Test?
This test is particularly important for patients with:
- Breast cancer, especially hormone receptor-positive subtypes
- Lung squamous cell carcinoma
- Bladder cancer and urothelial carcinomas
- Head and neck squamous cell carcinomas
- Patients with advanced or metastatic solid tumors
- Individuals who have failed conventional chemotherapy
- Patients seeking personalized treatment options
- Those with family history of cancer or genetic predisposition
Clinical Indications and Symptoms
Patients experiencing persistent symptoms such as unexplained weight loss, chronic pain, abnormal bleeding, or those with newly diagnosed solid tumors should discuss FGFR1 testing with their oncologist. The test is especially relevant when standard treatments have shown limited effectiveness or when exploring targeted therapy options.
Benefits of FGFR1 Solid Tumor Testing
- Personalized Treatment Planning: Identifies patients who may benefit from FGFR-targeted therapies
- Improved Treatment Outcomes: Enables selection of therapies specifically matched to genetic alterations
- Reduced Side Effects: Helps avoid ineffective treatments and their associated toxicities
- Comprehensive Molecular Profiling: Provides detailed genetic information for comprehensive cancer management
- Clinical Trial Eligibility: May qualify patients for novel targeted therapy clinical trials
- Prognostic Information: Offers insights into disease progression and potential treatment responses
Understanding Your Test Results
Your FGFR1 Solid Tumor Test results will be carefully interpreted by our expert molecular pathologists and genetic counselors:
Positive Results
A positive result indicates the presence of FGFR1 genetic alterations that may make your tumor susceptible to targeted therapies. Your oncologist will discuss specific treatment options, including FDA-approved FGFR inhibitors and clinical trial opportunities.
Negative Results
A negative result means no significant FGFR1 alterations were detected. This information helps guide treatment decisions away from FGFR-targeted therapies and toward other appropriate options.
Inconclusive Results
In rare cases, results may be inconclusive due to sample quality or technical factors. Our team will provide guidance on next steps, which may include retesting or alternative testing approaches.
Test Details and Pricing
| Test Component | Details |
|---|---|
| Test Name | FGFR1 Solid Tumor Test |
| Regular Price | $300 USD |
| Discount Price | $226 USD |
| Turnaround Time | 7-8 days |
| Sample Type | Tumor tissue (paraffin embedded tissue blocks) |
| Testing Method | FISH (Fluorescence In Situ Hybridization) |
Pre-Test Instructions
The FGFR1 Solid Tumor Test requires a doctor’s prescription. Please note that prescriptions are not applicable for surgery and pregnancy cases or individuals planning to travel abroad. Our team will coordinate with your healthcare provider to ensure proper sample collection and processing.
Nationwide Availability
We have branches across the United States, serving patients in all major cities including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more. Our nationwide network ensures convenient access to advanced genetic testing services.
Take Control of Your Cancer Treatment Journey
Don’t leave your treatment decisions to chance. The FGFR1 Solid Tumor Test provides the critical genetic information needed to make informed decisions about your cancer care. With our discounted price of $226 USD (regularly $300 USD), advanced genetic testing is more accessible than ever.
Ready to take the next step in your personalized cancer care?
Call us today at +1(267) 388-9828 to schedule your FGFR1 Solid Tumor Test or to speak with our genetic counseling team. Our specialists are available to answer your questions and guide you through the testing process.
Book your test now and join thousands of patients who have benefited from precision oncology through comprehensive genetic testing. Your journey toward personalized cancer treatment starts with understanding your tumor’s genetic profile.
